← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Motixafortide

FDA approved · Rx

CXCR4 antagonist peptide

Also known as: Aphexda, BL-8040, BKT140, 4F-benzoyl-TN14003, motixafortida, motixafortidum, TF14016, BKT 140

Evidence score
91/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 10 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Motixafortide, sold as Aphexda, is a synthetic cyclic peptide that blocks the CXCR4 receptor. CXCR4 and its signal CXCL12 help keep blood-forming stem cells anchored in the bone marrow, so blocking this interaction is thought to release those cells into the bloodstream where they can be collected.

What the evidence shows

Automatic summaryHuman trials

It is FDA approved for use with filgrastim to mobilize hematopoietic stem cells for collection and later autologous transplantation in adults with multiple myeloma. Other uses, such as in cancers like pancreatic cancer, have been studied in a small number of trials but are not established.

Key facts

Molecular formula
C97H144FN33O19S2
Molecular weight
2159.5 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

10registered studies
Phase 4most advanced phase
3completed (sample)
5recruiting (sample)

Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

Phase 3RecruitingNCT06514508

Motixafortide for MRD Sensitization in AML

Phase 2RecruitingNCT07392970

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Phase 2Active Not RecruitingNCT04543071

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

Phase 1CompletedNCT05293171

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

26papers referencing Motixafortide

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.

Nat Med2020

Clinical significance of chemokine receptor antagonists.

Expert Opin Drug Metab Toxicol2020

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.

Clin Cancer Res2021

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.

Nat Med2023

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.